Zhang W - Search Results

1

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.

Chen X, Pan X, Zhang W, Guo H, Cheng S, He Q, Yang B, Ding L. Chen X, et al. Among authors: zhang w. Acta Pharm Sin B. 2020 May;10(5):723-733. doi: 10.1016/j.apsb.2019.09.006. Epub 2019 Sep 25. Acta Pharm Sin B. 2020. PMID: 32528824 Free PMC article. Review.

2

Ceritinib increases sensitivity of AKT inhibitors to gastric cancer.

Wang J, Xu X, Wang T, Guo Q, Dai X, Guo H, Zhang W, Cheng S, Chen X, Ding L. Wang J, et al. Among authors: zhang w. Eur J Pharmacol. 2021 Apr 5;896:173879. doi: 10.1016/j.ejphar.2021.173879. Epub 2021 Jan 28. Eur J Pharmacol. 2021. PMID: 33515539 Free article.

3

Dihydropyridine Calcium Channel Blockers Suppress the Transcription of PD-L1 by Inhibiting the Activation of STAT1.

Pan X, Li R, Guo H, Zhang W, Xu X, Chen X, Ding L. Pan X, et al. Among authors: zhang w. Front Pharmacol. 2021 Jan 13;11:539261. doi: 10.3389/fphar.2020.539261. eCollection 2020. Front Pharmacol. 2021. PMID: 33519429 Free PMC article.

4

Tackling drug resistance in ovarian cancer with epigenetic targeted drugs.

Zhao L, Guo H, Chen X, Zhang W, He Q, Ding L, Yang B. Zhao L, et al. Among authors: zhang w. Eur J Pharmacol. 2022 Jul 15;927:175071. doi: 10.1016/j.ejphar.2022.175071. Epub 2022 May 27. Eur J Pharmacol. 2022. PMID: 35636522 Review.

5

The regulatory and modulatory roles of TRP family channels in malignant tumors and relevant therapeutic strategies.

Zhong T, Zhang W, Guo H, Pan X, Chen X, He Q, Yang B, Ding L. Zhong T, et al. Among authors: zhang w. Acta Pharm Sin B. 2022 Apr;12(4):1761-1780. doi: 10.1016/j.apsb.2021.11.001. Epub 2021 Nov 5. Acta Pharm Sin B. 2022. PMID: 35847486 Free PMC article. Review.

6

Butein suppresses PD-L1 expression via downregulating STAT1 in non-small cell lung cancer.

Zhao L, Zhang W, Luan F, Chen X, Wu H, He Q, Weng Q, Ding L, Yang B. Zhao L, et al. Among authors: zhang w. Biomed Pharmacother. 2023 Jan;157:114030. doi: 10.1016/j.biopha.2022.114030. Epub 2022 Nov 28. Biomed Pharmacother. 2023. PMID: 36455456 Free article.

7

Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling.

Ding L, Chen X, Zhang W, Dai X, Guo H, Pan X, Xu Y, Feng J, Yuan M, Gao X, Wang J, Xu X, Li S, Wu H, Cao J, He Q, Yang B. Ding L, et al. Among authors: zhang w. J Clin Invest. 2023 Jan 3;133(1):e154754. doi: 10.1172/JCI154754. J Clin Invest. 2023. PMID: 36594471 Free PMC article.

8

The impact of lipids on the cancer-immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy.

Zheng M, Zhang W, Chen X, Guo H, Wu H, Xu Y, He Q, Ding L, Yang B. Zheng M, et al. Among authors: zhang w. Acta Pharm Sin B. 2023 Apr;13(4):1488-1497. doi: 10.1016/j.apsb.2022.10.027. Epub 2022 Nov 2. Acta Pharm Sin B. 2023. PMID: 37139414 Free PMC article. Review.

9

Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA.

Zhang W, Pan X, Xu Y, Guo H, Zheng M, Chen X, Wu H, Luan F, He Q, Ding L, Yang B. Zhang W, et al. Acta Pharm Sin B. 2023 Jun;13(6):2585-2600. doi: 10.1016/j.apsb.2023.04.002. Epub 2023 Apr 17. Acta Pharm Sin B. 2023. PMID: 37425040 Free PMC article.

10

KLF12 transcriptionally regulates PD-L1 expression in non-small cell lung cancer.

Pan X, Zhang W, Wang L, Guo H, Zheng M, Wu H, Weng Q, He Q, Ding L, Yang B. Pan X, et al. Among authors: zhang w. Mol Oncol. 2023 Dec;17(12):2659-2674. doi: 10.1002/1878-0261.13512. Epub 2023 Sep 2. Mol Oncol. 2023. PMID: 37606530 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

87,534 results

Search Page

Filters